Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy.
CNS Drugs. 2023 Apr;37(4):351-361. doi: 10.1007/s40263-023-00997-7. Epub 2023 Mar 28.
To compare safety and functional outcomes of intravenous thrombolysis (IVT) between females and males with acute ischaemic stroke (AIS) in relation to preadmission use of antiplatelets.
Multicentre cohort study of patients admitted from 1 January 2014 to 31 January 2020 to hospitals participating in the Swiss Stroke Registry, presenting with AIS and receiving IVT. Primary safety outcome was in-hospital symptomatic intracerebral haemorrhage (sICH). Primary functional outcome was functional independence at 3 months after discharge. Multivariable logistic regression models were fitted to assess the association between sex and each outcome according to preadmission use of antiplatelets.
The study included 4996 patients (42.51 % females, older than males, median age 79 vs 71 years, p < 0.0001). Comparable proportions of females (39.92 %) and males (40.39 %) used antiplatelets before admission (p = 0.74). In total, 3.06 % females and 2.47 % males developed in-hospital sICH (p = 0.19), with similar odds (adjusted odds ratio, [AOR] 0.93, 95 % confidence interval, [CI] 0.63-1.39). No interaction was found between sex and preadmission use of either single or dual antiplatelets in relation to in-hospital sICH (p = 0.94 and p = 0.23). Males had higher odds of functional independence at 3 months (AOR 1.34, 95 % CI 1.09-1.65), regardless of preadmission use of antiplatelets (interaction between sex and preadmission use of either single or dual antiplatelets p = 0.41 and p = 0.58).
No sex differences were observed in the safety of IVT regarding preadmission use of antiplatelets. Males showed more favourable 3-month functional independence than females; however, this sex difference was apparently not explained by a sex-specific mechanism related to preadmission use of antiplatelets.
比较急性缺血性脑卒中(AIS)女性与男性患者在接受静脉溶栓(IVT)治疗前使用抗血小板药物的安全性和功能结局。
这是一项多中心队列研究,纳入了 2014 年 1 月 1 日至 2020 年 1 月 31 日期间在参与瑞士卒中登记处的医院就诊的 AIS 患者,并接受了 IVT 治疗。主要安全性结局为住院期间症状性颅内出血(sICH)。主要功能结局为出院后 3 个月的功能独立性。采用多变量逻辑回归模型,根据抗血小板药物的使用情况,评估性别与每种结局之间的关系。
本研究纳入了 4996 名患者(42.51%为女性,年龄大于男性,中位年龄 79 岁比 71 岁,p<0.0001)。女性(39.92%)和男性(40.39%)接受抗血小板药物治疗的比例相当(p=0.74)。共有 3.06%的女性和 2.47%的男性发生住院期间 sICH(p=0.19),其比值相似(校正比值比 [AOR]0.93,95%置信区间 [CI]0.63-1.39)。在考虑到使用单药或双联抗血小板药物的情况下,未发现性别与住院期间 sICH 之间存在交互作用(p=0.94 和 p=0.23)。无论是否使用抗血小板药物,男性患者在 3 个月时功能独立的可能性更高(AOR1.34,95%CI1.09-1.65)(性别与使用单药或双联抗血小板药物之间的交互作用 p=0.41 和 p=0.58)。
在接受 IVT 治疗前使用抗血小板药物的情况下,未观察到性别对 IVT 安全性的影响。与女性相比,男性患者在 3 个月时的功能独立性更有利;然而,这种性别差异显然不是由与接受 IVT 治疗前使用抗血小板药物相关的特定性别机制引起的。